INGELHEIM, Germany--(BUSINESS WIRE)--The first patient with atrial fibrillation (AF) has been enrolled in the global RE-CIRCUIT™ study.4 The study assesses the safety and efficacy of uninterrupted anticoagulation with dabigatran etexilate (Pradaxa®) during ablation procedures compared to warfarin.1 Results from the RE-CIRCUIT™ study are expected during 2016.
Help employers find you! Check out all the jobs and post your resume.
